Clinical trial
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
NCT00044148 · Chromaderm, Inc., Industry · Completed
Key facts
| NCT number | NCT00044148 |
|---|---|
| Title | The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes |
| Official title | The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial |
| Lead sponsor | Chromaderm, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | LY333531 |
| Start date | Jul 16, 2002 |
| Primary completion | Apr 28, 2004 |
| Completion | Apr 28, 2004 |
| First posted | Aug 21, 2002 |
| Last update posted | Feb 1, 2017 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: